Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWasana Prasitsuebsaien_US
dc.contributor.authorTim R. Cresseyen_US
dc.contributor.authorEdmund Capparellien_US
dc.contributor.authorNirun Vanpraparen_US
dc.contributor.authorKeswadee Lapphraen_US
dc.contributor.authorKulkanya Chokephaibulkiten_US
dc.description.abstractWe assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure. © 2012 by Lippincott Williams & Wilkins.en_US
dc.titlePharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuationen_US
article.title.sourcetitlePediatric Infectious Disease Journalen_US
article.volume31en_US Universityen_US Mai Universityen_US School of Public Healthen_US of California, San Diegoen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.